4. Discussion
knee OA, OA pain, knee pain, pain
In this randomized double-blind and controlled clinical study, dietary supplementation with an omega-3-based product administered for 8 weeks was effective in reducing persistent knee pain or discomfort in subjects over 40 years of age. Health-related QoL is receiving increasing attention as an outcome measure for knee pain based on scores of generic and knee-specific questionnaires, such as the WOMAC index. The self-administered WOMAC index is the most commonly used clinical tool for evaluating patients with knee OA [The benefits of dietary supplementation extend beyond just improvements in WOMAC scores. In this study, other important findings were a decrease in the time required to perform the TUG test after consuming AvailOmFurthermore, our study showed a significant decrease in pain perception when comparing the AvailOmThe efficacy of these dietary supplements aligns with a larger body of literature supporting the analgesic effects of foods and nutrients. Omega-3 fatty acid supplements, in particular, have been shown to reduce OA pain due to their anti-inflammatory and anti-nociceptive actions [Other randomized double-blind placebo-controlled studies have shown the analgesic efficacy and safety of The results are quite conclusive in this regard. The sleep variables that were modified by the consumption of some products are latency, wakefulness, and awakenings (number). None of these variables were modified in the group of subjects that consumed AvailOm; on the other hand, the subjects that consumed Boswellia improved their score in these variables. In the group that consumed Boswellia and AvailOm, the change that occurred was very similar to the change in the group that consumed only Boswellia. Therefore, with these results, it does not appear that AvailOm can modify these variables even as an enhancing mechanism.In relation to results regarding sleep variables, the consumption of As may be expected, the consumption of the product with AvailOmLimitations of the study include the reduced sample size and the duration of treatment of 8 weeks only. However, in relation to the selection of an 8-week supplementation period, in a previous publication of our group using omega-3 supplementation with DHA, activity and incorporation of the product into phospholipids of the erythrocyte membrane were observed at 30 days of starting supplementation with different doses [